
    
      To evaluate the safety of a single subcutaneous injection of ISIS 325568 administered at four
      increasing dose levels (50, 100, 200, 400 mg/week) and to evaluate the safety and
      tolerability of multiple doses of ISIS 325568 (three intravenous doses during Study Week 1,
      followed by once weekly subcutaneous administration for 5 weeks) at each of the four dose
      levels
    
  